Skip to main content
Premium Trial:

Request an Annual Quote

Quark Delayed Graft Function Drug Gets European Orphan Drug Status

Premium

Quark Pharmaceuticals this week announced that its investigational drug for the prevention of delayed graft function in kidney transplant patients has received an orphan drug designation from the European Commission.

The provisions for the EU orphan designation provide incentives to companies developing the products, including the potential for up to 10 years of market exclusivity and various fee reductions for certain regulatory activities, Quark said.

The drug, QPI-1002, is designed to temporarily inhibit p53, and received a similar designation from the US Food and Drug Administration earlier this year.

Last month, Quark announced that phase I data for QPI-1002 showed the compound to be safe, with no dose-limiting toxicities (GSN 5/6/2010).

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.